AbbVie dives deeper into eye care, paying $370M cash — with a $1.4B sweetener — to partner on VEGF gene therapy
AbbVie is expanding the ophthalmology segment of their pipeline today, bagging a gene therapy now in pivotal trials for wet age-related macular degeneration for a whopping $370 million in cash and adding $1.38 billion in milestone cash as a sweetener. And its new partners at Regenxbio also get support for future trial work.
In exchange, AbbVie gets to take the lead on the global commercialization effort — if it works — along with development work, with Regenxbio $RGNX jumping in alongside in the US.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.